Fig. 9
From: Multimodal lung cancer theranostics via manganese phosphate/quercetin particle
Biodistribution and non-invasive imaging of AHA@MnP/QCT NPs in vitro and in vivo. (A) Schematic illustration for AHA@MnP/QCT NPs involved in the biodistribution and non-invasive imaging; (B) Representative fluorescence images of NPs-treated mice in vivo at different time points (n = 3); (C) Radiant efficiency of fluorescence in Lewis cancer cell-bearing mice at different time points; (D) Fluorescence images of major organs and tumors obtained 24 h and 48 h postinjection; (E) Radiant efficiency of fluorescence in major organs and tumors; (F) T2-MRI images for different times of AHA@MnP/QCT NPs in HEPES buffer with different pH conditions (7.4, 6.5, 5.0); (H) T2-MRI images for different concentrations of AHA@MnP/QCT NPs in HEPES buffer with different pH conditions (7.4, 6.5, 5.0); (J) T2-MRI images for Lewis tumor bearing mice at various times, after the intravenous injection of AHA@MnP/QCT NPs; (L) T2-MRI images for Lewis tumor bearing mice at various concentrations, after the intravenous injection of AHA@MnP/QCT NPs; (G,I) Quantifcation of T2-MRI signal intensity of AHA@MnP/QCT NPs from F, H; (K,M) Quantifcation of T2-MRI signal intensity of tumor areas from J, L